Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Irhythm Technologies Inc (NQ: IRTC )

75.04 +2.60 (+3.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Irhythm Technologies Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies
Via Benzinga
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Earnings Preview For iRhythm Technologies
Via Benzinga
Beyond The Numbers: 9 Analysts Discuss iRhythm Technologies Stock
Via Benzinga
Key Takeaways From iRhythm Technologies Analyst Ratings
Via Benzinga
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
Exposures Political
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
Expert Ratings For iRhythm Technologies
Via Benzinga
4 Analysts Assess iRhythm Technologies: What You Need To Know
Via Benzinga
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services. 
Via Benzinga
Exposures Product Safety
Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
From iRhythm
Via GlobeNewswire
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
From iRhythm
Via GlobeNewswire
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
From iRhythm
Via GlobeNewswire
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring
iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM)... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Results of GUARD-AF Trial
From iRhythm
Via GlobeNewswire
Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday
Via Benzinga
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in Upcoming Investor Conferences in September
From iRhythm
Via GlobeNewswire
IRTC Stock Earnings: iRhythm Technologies Beats EPS, Beats Revenue for Q2 2024
IRTC stock results show that iRhythm Technologies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
iRhythm Technologies Announces Chief Financial Officer Transition
From iRhythm
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.